Health Condition 1: null- Polycystic ovary syndrome, clinical and biochemical changes
Conditions
Interventions
Intervention1: Ethinyl oestradiol with cyproterone acetate: 1 tab daily for 21 days then 7 days gap and to restart- for 6 months then evaluations and further 12 months.
Control Intervention1: nil: A c
Sponsors
DRSUDHINDRA MOHAN BHATTACHARYAConsultant SCDas Memorial Medical and Research Center Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: Polycystic ovary syndrome, as per Rotterdam criteria. age- 16-40 years.
Exclusion criteria
Exclusion criteria: Secondary causes of hyperandrogenism, as per Rotterdam criteria; history of hormone intake in the preceding 3 months; medical conditions contraindicated for combined hormone therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chages in clinical parameters like BMI, Waist-hip ratio; acbominal circumference; hirsutism score ; acne lesions; changes in serum total testosterone, SHBG(sex hormone binding globulin levels), Free androgen index,; insulin resistance as measured by fasting glucose- insulin ratio.Timepoint: First time of assessment - 6 months Second time of assessment - 12 months after start of the treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| side effects and compliance with the medicationTimepoint: first after 6 months and finally after 12 months. | — |
Countries
India
Contacts
Public ContactDRSUDHINDRA MOHAN BHATTACHARYA
Consultant, S.C.Das Memorial Medical and Researech Center, Kolkata
Outcome results
None listed